Flutiform ([fluticasone propionate + formoterol fumarate]; Vectura/Mundipharma/Kyorin) is a pressurized metered-dose inhaler formulation which contains a combination of fluticasone propionate and formoterol. Fluticasone propionate is an inhaled corticosteroid which has potent anti-inflammatory activity when delivered by inhalation, while formoterol fumarate is a long-acting beta 2 agonist which acts as a bronchodilator.
TABLE OF CONTENTS
4 Product Profiles
4 Flutiform : Asthma
LIST OF FIGURES
10 Figure 1: Asthma – current and future market dynamics analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Flutiform in asthma
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Flutiform in asthma
LIST OF TABLES
4 Table 1: Flutiform drug profile
6 Table 2: Flutiform pivotal trial data in asthma
9 Table 3: Flutiform Phase III trials in asthma
15 Table 4: Flutiform sales for asthma across Japan and the five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.